Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
grade D 6.34 -4.80% -0.32
SGMO closed down 4.8 percent on Friday, March 27, 2020, on 67 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical SGMO trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.80%
MACD Bullish Signal Line Cross Bullish -4.80%
Wide Bands Range Expansion -4.80%
Up 3 Days in a Row Strength -4.80%
Wide Bands Range Expansion 1.28%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Biotechnology Life Sciences Emerging Technologies Molecular Biology Glioblastoma Huntington's Disease Hemoglobinopathies Hemophilia A Hoffmann La Roche Lysosomal Storage Disorders

Is SGMO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.91
52 Week Low 4.81
Average Volume 2,522,838
200-Day Moving Average 9.36
50-Day Moving Average 7.26
20-Day Moving Average 6.81
10-Day Moving Average 5.96
Average True Range 0.72
ADX 23.39
+DI 17.31
-DI 20.22
Chandelier Exit (Long, 3 ATRs ) 7.04
Chandelier Exit (Short, 3 ATRs ) 6.96
Upper Bollinger Band 8.91
Lower Bollinger Band 4.70
Percent B (%b) 0.39
BandWidth 61.93
MACD Line -0.37
MACD Signal Line -0.41
MACD Histogram 0.0338
Fundamentals Value
Market Cap 531.74 Million
Num Shares 83.9 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -7.83
Price-to-Sales 42.92
Price-to-Book 5.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.79
Resistance 3 (R3) 6.82 6.70 6.72
Resistance 2 (R2) 6.70 6.59 6.69 6.69
Resistance 1 (R1) 6.52 6.51 6.46 6.49 6.66
Pivot Point 6.40 6.40 6.37 6.39 6.40
Support 1 (S1) 6.22 6.29 6.16 6.19 6.02
Support 2 (S2) 6.10 6.21 6.09 5.99
Support 3 (S3) 5.92 6.10 5.97
Support 4 (S4) 5.89